Company news

Crispr Therapeutics Ag (NASDAQ:CRSP) news

Crispr Therapeutics Ag news releases on 6ix. Latest, Apr 1, 2024: CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024…

Crispr Therapeutics Ag (NASDAQ:CRSP) news

Press releases — page 2

CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

CRISPR Therapeutics to Present at the Citi 2024 Virtual Oncology Leadership Summit

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics Highlights Strategic Priorities and 2024 Outlook

CRISPR Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

CRISPR Therapeutics Announces Preclinical Data at the American Heart Association (AHA) Scientific Sessions 2023

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

CRISPR Therapeutics Announces Leadership Transition

CRISPR Therapeutics to Participate in Citi's 18th Annual Biopharma Conference

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results

CRISPR Therapeutics to Participate Upcoming Investor Conferences

CRISPR Therapeutics to Participate in Needham’s 22nd Annual Healthcare Conference

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics Announces Departure of Board Member

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

CRISPR Therapeutics to Present at the American Association for Cancer Research 2023 Annual Meeting

CRISPR Therapeutics Announces Transition of Chief Financial Officer

CRISPR Therapeutics to Participate in the 43rd Annual Cowen Health Care Conference

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

CRISPR Therapeutics Provides Update on Its Ongoing Phase 1 CARBON™ Trial of CTX110®

Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition

CRISPR Therapeutics to Present at the 2022 BMO Growth & ESG Conference

CRISPR Therapeutics Presents Data at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

CRISPR Therapeutics Announces Poster Presentation on CTX110® at the American Society of Hematology (ASH) 2022 Annual Meeting

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results

CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer

CRISPR Therapeutics to Present at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

CRISPR Therapeutics to Present at the BMO Biopharma Spotlight Series: Gene Editing and Therapy

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress